MRSA Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global MRSA Testing Market Trends and Insights

Rising Demand for Rapid Infection-Control Decisions

Turnaround time has become a key purchasing consideration in the MRSA testing market. A 2025 comparative study found that the Eazyplex MRSA Plus LAMP assay identified MRSA within 1 hour of positive blood-culture processing, with 100% sensitivity and specificity across 109 blood cultures. This supports same-shift isolation decisions, compared with culture workflows that may require 48 hours. The study found inappropriate empirical therapy in 47% of patients with MRSA bacteremia, while more than 90% of methicillin-susceptible cases received unnecessarily broad-spectrum treatment.^{[1]Brandt C, “Diagnostic Methods and Protocols for Rapid Determination of Methicillin Resistance in Staphylococcus aureus Bloodstream Infections, A Comparative Analysis,” European Journal of Clinical Microbiology & Infectious Diseases, springer.com} Pharmacist-led MRSA nasal PCR protocols have reduced empirical vancomycin duration, and active surveillance guidance indicates that clinical cultures alone can understate total hospital MRSA prevalence by up to 85%.

Growth of Automated Sample-to-Answer Molecular Platforms

The MRSA testing market is moving from open PCR workflows toward enclosed systems that integrate sample processing and detection. These platforms reduce reliance on specialist microbiology staff and extend molecular testing to smaller hospitals. A 2025 Lab on a Chip study described a compact platform that detected MRSA in human serum at 1 CFU per reaction within 45 minutes, integrating bacterial lysis, nucleic-acid purification, and colorimetric LAMP on a single chip.^{[2]Huang SS, “SHEA/IDSA/APIC Practice Recommendation, Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute-Care Hospitals, 2022 Update,” Infection Control & Hospital Epidemiology, cambridge.org} A 2025 meta-analysis reported a pooled sensitivity of 99% and a specificity of 100% for CRISPR-based MRSA detection across clinical samples. As automated systems expand into dialysis and long-term-care settings, instrument placements can increase recurring reagent demand.^{[3]Buetti N, “Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control, Clinical and Economic Impact,” Clinical Infectious Diseases, academic.oup.com} At the same time, FDA requirements for Class II MRSA nucleic-acid amplification devices establish a validation threshold for new systems.

Expansion of Active Surveillance in High-Risk Care Pathways

Active surveillance testing creates protocol-driven demand that is less dependent on individual physician orders. Updated SHEA, IDSA, and APIC recommendations identify active surveillance as an additional practice for high-risk groups, including intensive care patients, dialysis recipients, and recently discharged patients. California requires MRSA active surveillance testing for specified admission categories in acute-care facilities, making hospital occupancy and patient volumes key drivers of testing volumes alongside infection epidemiology. A 2026 study of Japanese geriatric long-term-care facilities found transmission routes that conventional surveillance had not detected. This finding supports molecular screening during transitions between facilities, while electronic health record links can help automate testing orders.

Digital Epidemiology and Community-Associated Detection Needs

The MRSA testing market is expanding through genome-based surveillance and testing beyond hospital wards. A 2-year MRSA genomic surveillance program at UPMC Presbyterian Hospital identified 172 transmission clusters containing 476 isolates. It was associated with 62 prevented infections, 4.8 prevented deaths, USD 695,706 in net savings, and a 3.2-fold return on investment. Nanopore sequencing and genomic analysis identified a neonatal intensive care unit outbreak 13 days after the first positive culture. These programs enable infection-prevention teams to identify transmission patterns that routine microbiology results may not reveal. Community-associated MRSA bloodstream infections have also increased in Canada since 2019, expanding demand across emergency, outpatient, and harm-reduction services.

High Per-Test Cost and Capital Intensity of Molecular Systems

Closed-cartridge PCR systems have higher reagent costs than chromogenic culture media, limiting adoption in budget-constrained laboratories. High-throughput automated systems may require capital expenditures ranging from the mid-six figures to the low-seven figures in USD, in addition to service agreements, trained personnel, quality processes, and recurring cartridge supplies. Community hospitals and long-term care facilities may lack the testing volumes required to justify this investment. A WHO 2025 analysis found that automated molecular systems were primarily concentrated in Level III and IV laboratories in high-income countries. 

Reimbursement and Screening-Policy Variability

Reimbursement policies can determine whether providers order MRSA molecular tests in outpatient and perioperative settings. A Blue Cross Blue Shield policy effective in November 2025 allowed possible reimbursement for MRSA-specific nucleic acid amplification tests but excluded direct-probe tests and combined amplified-probe and quantification orders during the same encounter. These distinctions can affect the clinical settings in which laboratories offer rapid testing without incurring unreimbursed costs.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Test Type: Molecular Platforms Lead, While Immunodiagnostics Expand in Point-of-Care Settings

Molecular diagnostic tests held a 48.96% share of the MRSA testing market in 2025, driven by cartridge-based PCR platforms for mecA and mecC detection in nasal swabs, blood cultures, and skin and soft tissue specimens. These systems support rapid testing in high-acuity and perioperative care settings. Culture-based tests remain important for antibiotic susceptibility profiling and confirmation, although their 48- to 72-hour turnaround limits use in time-sensitive decisions. Immunodiagnostic tests are the fastest-growing category, with a projected CAGR of 7.32% from 2026 to 2031. Lateral-flow and PBP2a assays can deliver results within 5 minutes from blood culture pellets when PCR systems are unavailable.

A 2025 comparative study found that the Clearview PBP2a method identified all mecA-positive isolates in clinical and spiked blood cultures when combined with rapid species identification. This capability positions immunodiagnostic tests as a practical complement to molecular confirmation in resource-constrained settings. The Others category includes MALDI-TOF MS and emerging CRISPR-based tests. MALDI-TOF subtyping from blood culture pellets achieved 59.8% accuracy in MRSA determination, while CRISPR-based methods showed high pooled diagnostic performance in a 2025 review. FDA performance controls favor developers that meet established validation requirements.

By Product Type: Reagents Support Recurring Revenue, While Instruments Gain From Automation

Reagents and kits held 58.66% of MRSA testing revenue in 2026, supported by recurring purchases across molecular, culture-based, and immunodiagnostic workflows. Installing PCR instruments and automated microbiology systems creates sustained demand for assay consumables, providing resilience when laboratories replace or upgrade equipment. Instruments are the fastest-growing product category, with a projected CAGR of 8.55% from 2026 to 2031. Growth reflects rising laboratory automation in high-income markets and expanding diagnostic infrastructure in emerging markets.

In April 2025, BD received FDA 510(k) clearance for the BD Phoenix M50 and BDXpert System. The system combines microbial identification and rule-based antimicrobial susceptibility interpretation through the BD Synapsys Informatics Solution. Multiplex panels can detect MRSA, methicillin-susceptible S. aureus, coagulase-negative staphylococci, and resistance genes from a single sample. This approach can increase revenue per sample, reduce testing workload, and support reporting of multiple organisms and resistance markers through a common specimen workflow.

By End User: Hospitals Lead Testing Volume, While Laboratories Take Complex Profiling

Hospitals and clinics held 61.45% of MRSA testing revenue in 2025, supported by mandatory surveillance, preoperative screening, and high-acuity patient populations. Intensive care, dialysis, and post-surgical patients often require repeated testing. In the United States, bundled payment structures may encourage screening by linking surgical-site infections to hospital financial outcomes. Diagnostic and pathology laboratories are the fastest-growing end-user group, with a projected CAGR of 9.34% from 2026 to 2031.

The growth of diagnostic and pathology laboratories reflects the transfer of whole-genome sequencing, multiplex panel testing, and complex resistance profiling to reference-level facilities. The MRSA testing industry is increasingly separating routine near-patient identification from centralized genomic and susceptibility analysis. Academic and research institutes hold a smaller revenue share but remain important for technology validation, generating clinical evidence for FDA 510(k) and CE-IVDR submissions. They also serve as early adopters of sequencing-based surveillance tools.

Geography Analysis

North America accounted for 42.80% of the MRSA testing market share in 2025. Established hospital-onset surveillance, preoperative screening, and antibiotic stewardship programs in the United States and Canada support diagnostic testing before surgery, at admission, and during suspected transmission events. A CDC analysis across six surveillance sites found that community-associated MRSA incidence increased before the pandemic and that hospital-onset incidence remained above prepandemic levels in 2021 and 2022. Canada has recorded a sustained increase in community-associated MRSA bloodstream infection rates since 2019, while Mexico and South America remain earlier-stage markets where culture-based methods are widely used alongside emerging automated molecular platforms.

Europe presents a mixed demand environment for the MRSA testing market. The European Union recorded an MRSA bloodstream infection incidence of 4.48 per 100,000 population in 2024, below the 2030 target of 4.79 per 100,000 population, which may constrain testing growth from hospital-onset infections in Western Europe. However, some Southern, Central, and Eastern European countries reported incidence rates as high as 13.63 per 100,000 population. The United Kingdom, Germany, and France are investing in genome-based surveillance, while CE-IVDR requirements continue to affect product launch timelines across Europe.

Asia-Pacific is the fastest-growing region, with the MRSA testing market projected to expand at a CAGR of 9.89% from 2026 to 2031. Hospital expansion, infection-control requirements, and high MRSA prevalence support growth, while China is expanding molecular capacity in public hospitals, and rural facilities continue to rely on culture-based testing. India’s private hospital chains are deploying PCR-based systems in transplant and orthopedic units, while Japan and South Korea maintain stringent surveillance practices; a 2026 Japanese long-term-care study identified undetected inter-facility MRSA transmission.